- Divestiture Supports Company Focus on Development and Commercialization of Abecma-
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 3/26/2026 | Peer Perform | Wolfe Research | ||
| 3/18/2026 | Underperform | Bernstein | ||
| 3/18/2026 | $175.00 | Outperform | Bernstein | |
| 3/10/2026 | $42.00 | Buy → Hold | TD Cowen | |
| 3/3/2026 | $40.00 | Underweight → Equal-Weight | Morgan Stanley | |
| 3/2/2026 | $41.00 | Buy → Neutral | Goldman | |
| 2/24/2026 | Buy → Hold | Kepler | ||
| 2/24/2026 | Overweight → Neutral | Analyst |
For Immediate Release: March 08, 2024 Today, the U.S. Food and Drug Administration approved a new indication for use for Wegovy (semaglutide) injection to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease and either obesity or overweight. Wegovy should be used in addition to a reduced calorie diet and increased physical activity. Cardiovascular disease is a gr
6-K - NOVO NORDISK A S (0000353278) (Filer)
6-K - NOVO NORDISK A S (0000353278) (Filer)
6-K - NOVO NORDISK A S (0000353278) (Filer)
Average weight loss of ~21% at 72 weeks in adults with obesity if all patients stayed on treatment* with Wegovy® HD (~19% regardless of whether patients stayed on treatment**) in the STEP UP trial1In the STEP UP trial, about one in three trial participants taking Wegovy® HD achieved 25% weight loss or higher1This approval for Wegovy® further expands its already robust label inclusive of multiple formulations, including Wegovy® pill, and indications not available with other GLP-1 weight loss medicinesPLAINSBORO, N.J., March 19, 2026 /PRNewswire/ -- Novo Nordisk today announced US Food and Drug Administration (FDA) approval of a new higher dose of Wegovy®, Wegovy® HD (semaglutide) injection 7.
Average weight loss of ~17% if all patients stayed on treatment* with Wegovy® (semaglutide) tablets 25 mg (~14% regardless of if patients stayed on treatment**) in the OASIS 4 trial1Starting dose of Wegovy® pill (1.5 mg) available today for only $149 per month (or $5 per day) via easy to access self-pay offerWegovy® pill now broadly available through 70,000+ US pharmacies such as CVS and Costco, select telehealth providers including Ro, LifeMD and Weight Watchers, NovoCare® Pharmacy, GoodRx and morePLAINSBORO, N.J.and BAGSVÆRD, Denmark, Jan. 5, 2026 /PRNewswire/ -- Wegovy® pill is now available, providing those seeking help with their weight the revolutionary science of GLP-1 medicine in a p
Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, Dec. 31, 2025 /PRNewswire/ -- USA News Group News Commentary – Recent clinical trials achieving 83% insulin independence rates have ignited a dramatic shift in metabolic disease investment[1], with late-2025 M&A activity reaching record valuations as major pharmaceutical companies race to secure curative platforms over symptom-management franchises[2]. This pivot toward functional cures rather than chronic insulin dependence is defining the strategic roadmaps of Avant Technologies, Inc. (OTCQB:AVAI), Novo Nordisk A/S (NYSE:NVO), Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN), Viking Therapeutics, Inc. (NASDAQ:VKTX), and Tandem Diabetes C
4 - 2seventy bio, Inc. (0001860782) (Issuer)
4 - 2seventy bio, Inc. (0001860782) (Issuer)
4 - 2seventy bio, Inc. (0001860782) (Issuer)
4 - 2seventy bio, Inc. (0001860782) (Issuer)
4 - 2seventy bio, Inc. (0001860782) (Issuer)
Wolfe Research initiated coverage of Novo Nordisk A/S with a rating of Peer Perform
Bernstein initiated coverage of Novo Nordisk A/S with a rating of Underperform
Bernstein initiated coverage of Novo Nordisk A/S with a rating of Outperform and set a new price target of $175.00
SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Dr. Hardean Achneck as Chief Medical Officer, effective immediately. Dr. Achneck will lead the Company's global clinical development efforts and serve as a member of Aligos' Senior Leadership Team. Dr. Hardean Achneck is a seasoned clinical development executive with extensive experience across multiple therapeutic areas, including hepatology and infectious diseases. "I am excited to welcome Hardean to Aligos a
2seventy bio, Inc. (NASDAQ:TSVT), announced today that Eli Casdin, Chief Investment Officer, and Founder of Casdin Capital, and Charles Newton, Chief Financial Officer, Lyell Immunopharma, have been appointed as new independent members of the Company's Board of Directors (the "Board"), effective immediately. Casdin Capital owns approximately 2.3% of 2seventy bio's outstanding shares as of 03/20/24. "We are pleased to welcome Eli and Charlie to the 2seventy Board," said Dan Lynch, chair of the Board of Directors. "Eli is a highly regarded, leading life sciences and healthcare investor and has a deep understanding of and history with the Company. Charlie has a track record of helping compan
Believes 2seventy Could Be Conservatively Worth ~$9 Per Share if the Company Exclusively Focuses on Its Most-Valuable Asset Abecma, Reduces Corporate Overhead and Makes Improvements to the Composition of the Management Team and Board Engine Capital LP, which owns approximately 3% of 2seventy bio, Inc.'s (NASDAQ:TSVT) ("2seventy" or the "Company") outstanding shares, today announced that it sent the below letter the Company's Board of Directors (the "Board"). *** December 6, 2023 2seventy bio, Inc. 60 Binney Street Cambridge, MA 02142 Attention: Board of Directors Dear Members of the Board: Engine Capital LP (together with its affiliates, "Engine" or "we"), is a meaningful shareh
In the news release, Metsera Receives Amended Proposal from Novo Nordisk; Metsera Declares Novo Nordisk Amended Proposal "Superior", issued 04-Nov-2025 by Metsera, Inc. over PR Newswire, we are advised by the company that the second paragraph, third sentence, should begin "Shortly thereafter,..." rather than "On the same day,...", and the third paragraph, first sentence, should read "...representing up to $24.00 per share in cash (up from $21.25)..." rather than "...representing up to $24.00 per share in cash (up from $22.50)..." as originally issued inadvertently. The complete, corrected release follows: Metsera Receives Amended Proposal from Novo Nordisk; Metsera Declares Novo Nordisk Ame
Novo Nordisk Amended Proposal Values Metsera at up to $86.20 per Share, a Total of Approximately $10.0 Billion Superior to Revised Pfizer Proposal that Valued Metsera at up to $70.00 per Share, a Total of Approximately $8.1 Billion Pursuant to Pfizer Merger Agreement, Metsera and Pfizer May Negotiate Potential Adjustments for Two Business Days Pfizer Merger Agreement Remains in Effect; No Action Required by Metsera Shareholders NEW YORK, Nov. 4, 2025 /PRNewswire/ -- Metsera, Inc. (NASDAQ:MTSR) ("Metsera") today announced that its Board of Directors had determined, after consultation with its outside counsel and financial advisors, that a revised proposal that Metsera received from Novo Nord
Metsera Declares Novo Nordisk Proposal "Superior" Novo Nordisk Proposal Values Metsera at up to $77.75 per Share, a Total of Approximately $9 Billion Pursuant to Pfizer Merger Agreement, Metsera and Pfizer May Negotiate Potential Adjustments to Existing Transaction Pfizer Merger Agreement Remains in Effect; No Action Required by Metsera Shareholders NEW YORK, Oct. 30, 2025 /PRNewswire/ -- Metsera, Inc. (NASDAQ:MTSR) ("Metsera") today announced that its Board of Directors had determined, after consultation with its outside counsel and financial advisors, that an unsolicited proposal that Metsera received from Novo Nordisk A/S (Nasdaq Copenhagen: NOVO B) ("Novo Nordisk") to acquire Metsera (th
SC 13G/A - 2seventy bio, Inc. (0001860782) (Subject)
SC 13G/A - 2seventy bio, Inc. (0001860782) (Subject)
SC 13G/A - 2seventy bio, Inc. (0001860782) (Subject)